Drug
S 892216
S 892216: highest development phase Phase 2, developed by Shionogi. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| S-892216 NCT06928051 | Phase 2 | COVID-19 |
| S-892216 NCT06751017 | Phase 1 | COVID-19 |
Latest
No recent events.
Follow S 892216 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.